Article

Actavis Launches Generic Temovate Cream

Author(s):

Actavis has launched the generic version of Fougera's clobetasol propionate cream 0.05% (Temovate)

Actavis has launched the generic version of Fougera’s clobetasol propionate cream 0.05% (Temovate), a high-potency topical formulation designed to relieve inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adults.

Over a 12-month period ending on January 15, 2015, Temovate generated total US brand and generic sales of approximately $185 million, according to IMS Health.

The preparation contains clobetasol propionate, a synthetic corticosteroid for topical dermatologic use. The FDA warns that Temovate should not be used beyond 2 consecutive weeks, as the drug has the potential to suppress the hypothalamic-pituitary-adrenal axis.

The only adverse effect observed in patients who have used Temovate is a burning sensation at the application area.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Image credit:  kitsawet | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com